Prognostic Value of Absolute Lymphocyte count, Lymphocyte percentage, Serum albumin, Aberrant Expression of CD7, CD19 and the Tumor Suppressors (PTEN and p53) in Patients with Acute Myeloid Leukemia

Sadek, Nayera; Abdel-Tawab, Suzan M.; Assem, Nagwa M.; Hamdy, Hoda; Sayed, Fatma; Ahmad, Mohammad Abdel-Rhman; Elhamammy, Reem Hassan

doi:10.31557/apjcb.2020.5.4.131-140

Cited by 8 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flow cytometry also aids in the identification of minimal residual disease by identifying aberrant antigen expression. Some clinicians believe that patients with aberrant CD7 antigen expression exhibit a shorter survival time and are more likely to exhibit non-responsive behavior to the recommended treatment protocol than CD7-negative patients [ 21 ]. Further studies should be performed in this regard, including in our local population, to determine the frequency of aberrant antigen expression, including that of CD7, and to establish the impact of CD7 expression on treatment response, recurrence, and overall survival.…”

Section: Discussionmentioning

confidence: 99%

The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients

Raza¹,

Fatima²,

Noor³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundAberrant phenotype expression in acute myeloid leukemia (AML) may be due to genetic defects and is associated with a poor prognosis. CD7 is the first T-cell-associated antigen to be expressed during Tlymphocyte maturation. Aberrant expression of CD7 in AML influences clinical response, remission rate, and overall survival in these patients. ObjectiveTo determine the frequency of aberrant CD7 expression in patients with AML. Materials and methodsThis cross-sectional study was performed over a period of 12 months from July 2020 to June 2021 in the Hematology Department, Chughtai Lab, Lahore. This study included 120 patients who were newly diagnosed with AML. The following tests were performed for included patients: complete blood count (CBC), peripheral blood smear analysis, and flow cytometric analysis using a blood sample or bone marrow aspirate. Blast cells were analyzed for aberrant CD7 expression. Calculation of the sample size was performed by using the Select Statistics calculator. All statistical analyses were performed using SPSS ver. 23 software (IBM Corp., Armonk, NY). Data were expressed as frequencies, means ± standard deviation (SD), and percentages. ResultsOf 120 patients newly diagnosed with AML, the CD7 antigen was aberrantly expressed in 36 cases (30%). Of these patients, the AML2 subtype was the most common type of AML with aberrant CD7 expression, followed by AML M4, AML M1, M3, AML M5, and AML M0, respectively. ConclusionIn our study, aberrant CD7 expression occurred at a high frequency in acute myeloid leukemia. Thus, this marker should be added to the current flow cytometry panels.

show abstract

Section: Discussionmentioning

confidence: 99%

The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients

Raza¹,

Fatima²,

Noor³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…TP53 is known as a marker that can predict therapeutic response and prognosis in squamous cell lung carcinoma (Feng Xu et al, 2020, Kobayashi et al, 2015. In addition, its higher level detection was associated with better prognosis in other cancers, namely, acute myeloid leukemia (Sadek, 2020).…”

Section: Tp53 and Egfr Mutational Status In Thymoma: A Genetic Sequencing Studymentioning

confidence: 99%

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study

Syahruddin

Zaini

Sembiring

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Thymoma staging, histologic type, and complete eradication through any treatment modalities are significant to increase the survival of patients and reduce its recurrence rate. Prognosis of thymoma is worse at higher stages of the disease. The patients at the advanced stage of the thymoma have a 5-year median survival of 69%. Currently, the treatment choice in thymoma is surgery providing a better prognosis (Detterback et al.,

show abstract

“…Then they were exposed to an Anti-CD4 antibody for 20 minutes at 4°C and finally, these cells were analyzed with a PAS II flow cytometer (Partec GmbH, Munster, Germany) (16). Serum levels of IL-11 and IL-17 were determined by ELISA using ELISA kits protocol (Bender MedSystems GmbH, Vienna, Austria) (17).…”

Section: Cell Count and Serum Level Determinationmentioning

confidence: 99%

The relationship between different interleukins and T helper cells count in patients with immune thrombocytopenia

Hou

Yan

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Immune thrombocytopenia is the most common autoimmune disorder involving blood types. In several studies, the role of T CD4+ cells in patients with immune thrombocytopenia has been associated with different results. Therefore, in this study, with the aim of applied research in the pathogenesis of immune thrombocytopenia, the relationship was investigated between the number of T CD4+ cells, serum levels of IL-11 and IL-17 cytokines, and platelet count. In this regard, 100 patients with immune thrombocytopenia and 100 healthy individuals were included in the study. The T CD4+ cell counts were examined by flow cytometry and in addition, serum levels of interleukins 11 and 17 were measured by ELISA. The results of this study showed that the number of T CD4+ cells and plasma level of IL-17 were not significantly different between the two groups, but plasma levels of IL-11 in the patient group were significantly higher than the control group (P = 0.286). Overall, in this study, the level of cytokine IL-11 was significantly increased in comparison with IL-17 and T CD4+ cells in patients with immune thrombocytopenia, so it is suggested that measurement of cytokine IL-11 level in these patients could be considered as a critical diagnostic marker and indicator in the stages of disease progression.

show abstract

Prognostic Value of Absolute Lymphocyte count, Lymphocyte percentage, Serum albumin, Aberrant Expression of CD7, CD19 and the Tumor Suppressors (PTEN and p53) in Patients with Acute Myeloid Leukemia

Cited by 8 publications

References 30 publications

The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients

The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study

The relationship between different interleukins and T helper cells count in patients with immune thrombocytopenia

Contact Info

Product

Resources

About